...
首页> 外文期刊>Asian Pacific Journal of Cancer Prevention >Identification of Patients with Microscopic Hematuria who are at Greater Risk for the Presence of Bladder Tumors Using a Dedicated Questionnaire and Point of Care Urine Test - A Study by the Members of Association of Urooncology, Turkey
【24h】

Identification of Patients with Microscopic Hematuria who are at Greater Risk for the Presence of Bladder Tumors Using a Dedicated Questionnaire and Point of Care Urine Test - A Study by the Members of Association of Urooncology, Turkey

机译:使用专用调查问卷和护理点的膀胱肿瘤存在的微观血尿患者的鉴定患者患有膀胱肿瘤的存在和尿液测试 - 土耳其教育学协会成员的研究

获取原文
           

摘要

In patients with microscopic hematuria there is a need for better identification of those who are at greater risk of harbouring bladder tumors. The RisikoCheck(C) questionnaire has a strong correlation with the presence of urothelial carcinoma (UC) of the bladder and in combination with other available tests may help identify patients who require detailed clinical investigations due to increased risk of presence of bladder tumors. This study aimed to evaluate the efficacy of RisikoCheck(C) questionnaire together with NMP-22(R) (BladderChek(R)) as a point-of-care urine test in predicting the presence of bladder tumors in patients presenting with microscopic hematuria as the sole finding. In this multi-institutional prospective evaluation of 303 consecutive patients without a history of urothelial carcinoma (UC), RisikoCheck(C) risk group assessment, urinary tract imaging and cystourethroscopy as well as urine cytology and Nuclear Matrix Protein-22 (NMP-22 BladderChek) testing were performed where available. The sensitivity, specificity, negative predictive value (NPV), and positive predictive values (PPV) for the risk adapted approach were calculated. All patients underwent cystoscopy, and tumors were detected in 18 (5.9%). Urine cytology and NMP-22 was positive for malignancy in 9 (3.2%) and 12 (7.5%) of patients, respectively. A total of 43 (14%) patients were in the high risk group according to the RisikoCheck(C) questionnaire. The sensitivity and specificity of the questionnaire in detecting a bladder tumor was 61.5 % and 84.0 % in the high risk group. In patients with either a positive NMP-22 test or high risk category RisikoCheck(C), 23.6% had bladder tumors with a corresponding sensitivity of 54.2% and specificity of 88.6%. If both tests were negative only 3.3% of the patients had bladder tumors. The results of our study suggest that the efficacy of diagnostic evaluation of patients with microscopic hematuria may be further enhanced by combining RisikoCheck(C) questionnaire with NMP-22.
机译:在微观血尿患者中,需要更好地识别那些更具患有膀胱肿瘤的风险。 Risikocheck(c)调查问卷与膀胱尿路上皮癌(UC)的存在具有强烈的相关性,并且与其他可用试验组合可能有助于鉴定由于膀胱肿瘤的存在风险增加,因此需要鉴定需要进行详细的临床研究的患者。该研究旨在评估risikock(c)调查表与NMP-22(R)的疗效(Bladderchek(R))作为预测患有微观血尿的患者膀胱肿瘤存在的护理点尿液试验唯一的发现。在这种多机构前瞻性评估中,在没有尿路皮癌(UC)的连续患者,risikocheck(c)风险组评估,尿道成像和膀胱内脏诊断以及尿液细胞学和核基质蛋白-22(NMP-22 Bladderchek )在可用的地方进行测试。计算了风险适应方法的敏感性,特异性,负预测值(NPV)和阳性预测值(PPV)。所有患者接受膀胱镜检查和肿瘤,在18(5.9%)中检测到。尿液细胞学和NMP-22分别为8(3.2%)和12名(7.5%)患者的恶性肿瘤阳性。根据Risikocheck(C)问卷,共有43名(14%)的患者在高风险组中。检测膀胱肿瘤的调查表的敏感性和特异性为高风险组的61.5%和84.0%。在患有阳性NMP-22试验或高风险类别的患者中,Risikocheck(C),23.6%具有膀胱肿瘤,相应的敏感性为54.2%,特异性为88.6%。如果两个测试均为负,只有3.3%的患者患有膀胱肿瘤。我们的研究结果表明,通过将Risikocheck(C)调查表与NMP-22组合,可以进一步增强微观血尿患者诊断评价的疗效。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号